Using real-world data from over 640 patients with pancreatic cancer, this landmark study demonstrated a 2.2 fold increase in progression-free survival for those being treated with a molecularly-matched therapy. Attached is a pdf of the press release.
Perthera and the Pancreatic Cancer Action Network Publish Landmark Precision Medicine Study
AI-enabled precision, speed and scale
Precision oncology and speed to decision, for everyone, at every point of care.How We Help